Intec Pharma (NASDAQ: NTEC) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Intec Pharma to related businesses based on the strength of its valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.
Risk & Volatility
Intec Pharma has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, Intec Pharma’s competitors have a beta of 6.15, suggesting that their average share price is 515% more volatile than the S&P 500.
This is a summary of recent recommendations and price targets for Intec Pharma and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Intec Pharma Competitors||867||3223||11703||232||2.71|
Intec Pharma currently has a consensus target price of $12.00, suggesting a potential upside of 144.90%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 45.99%. Given Intec Pharma’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Intec Pharma is more favorable than its competitors.
Earnings and Valuation
This table compares Intec Pharma and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Intec Pharma||N/A||-$13.36 million||N/A|
|Intec Pharma Competitors||$284.49 million||$33.78 million||82.67|
Intec Pharma’s competitors have higher revenue and earnings than Intec Pharma.
Institutional & Insider Ownership
40.2% of Intec Pharma shares are owned by institutional investors. Comparatively, 50.0% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 17.1% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This table compares Intec Pharma and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Intec Pharma Competitors||-5,302.25%||-218.50%||-39.57%|
About Intec Pharma
Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs. The Company is focusing on the clinical development program for the Phase III clinical study of the Accordion Pill Carbidopa Levodopa (AP-CDLD), for the treatment of advanced stages Parkinson’s disease patients. Its pipeline also comprises The Accordion Pill-Zaleplon, a drug for sleep onset, which is in Phase II clinical program. Furthermore under research is Accordion Pill-Undisclosed Drug for the prevention and treatment of small bowel non-steroidal anti-inflammatory drug (NSAID) induced ulcers.
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.